Thus, although GLP-1R/GIPR agonists may result in significant weight loss, the co-administration of dual GLP-1R/GIPR agonists could potentially shield patients from concurrent osteoporosis by exploiting the inherent antiresorptive properties of GIP and GLP-1. Here, GCG is linked to osteoporosis.